Aurora Spine Stock Price, News & Analysis

Aurora Spine Corporation (OTCQB: ASAPF) has been awarded the 2022 Annual Spine Technology Award for its innovative DEXA Technology™ Bone Density-Matched Interbody Implants. Recognized by RRY Publications LLC and Orthopedics this Week, this technology adjusts spinal implants to match patients’ bone density, enhancing surgical outcomes. The award will be presented at the 37th Annual Meeting of the North American Spine Society in Chicago. Aurora Spine emphasizes that DEXA Technology™ represents a significant advancement in spinal implants, merging conventional machining, 3D printing, and additive manufacturing.

Aurora Spine Corporation (OTCQB: ASAPF) has received FDA 510(k) clearance for its SiLO TFX MIS Sacroiliac Joint Fixation System. This patented device is designed to enhance patient outcomes in spinal surgery through minimally invasive techniques. A detailed announcement regarding this system is expected on October 6, 2022. The clearance is a significant milestone for Aurora Spine, as it underscores the company's commitment to advancing spinal care technology.

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced its participation in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company will present a panel discussion titled Simplifying the Complex, featuring CEO Trent Northcutt and Clinical Education Director Krissy Ramey, available at 9:00 AM ET on September 28. Virtual 1x1 meetings with management will also be conducted. Aurora Spine focuses on innovative spinal implant technologies aimed at improving surgical outcomes, with more information available on their website.

Aurora Spine Corporation reported record quarterly revenue of $4.1 million for Q2 2022, marking a 68% year-over-year increase and 15% sequential growth from Q1. The company achieved positive EBITDAC of $96,285 compared to losses in previous quarters. Key highlights include receiving FDA clearances for the ZIP™ family of implants and the DEXA SOLO-L™ spinal fusion system, along with the issuance of a new patent for ZIPFlex™ Technology. The gross margin improved to 52.6%, reflecting successful sales strategies and increased use of proprietary products.

Aurora Spine Corporation (TSXV: ASG; OTCQB: ASAPF) has announced it will release its financial results for the second quarter ended June 30, 2022, on August 29, 2022. The management will host a conference call that same day at 11:00 a.m. Eastern Time to discuss the results. Interested parties can access the call via phone or a live webcast. Aurora Spine is dedicated to developing innovative medical devices aimed at improving spinal surgery outcomes. The company urges caution regarding forward-looking statements, as actual results may vary significantly due to various risks and uncertainties.

Aurora Spine Corporation (OTCQB: ASAPF) announced FDA clearance for its ZIP™ series of minimally invasive spinal implants to treat Lumbar Spinal Stenosis, expanding its indications beyond degenerative disc disease and spondylolisthesis. This new indication aims to address a growing patient population, estimated to increase by 18 million over the next decade. The ZIP device features a patented one-step locking mechanism, reducing surgery time and recovery. CEO Trent Northcutt highlighted this achievement as a key milestone for Aurora, enhancing patient care options while supporting the company's growth strategy.

Aurora Spine Corporation (ASAPF) recently announced the issuance of United States Patent No: 11,331,199 for its ZIPFlex™ Technology. This patent covers a minimally invasive interlaminar implant designed for motion preservation and fusion in spinal surgeries. The ZIPFlex device allows surgeons to perform motion preservation operations or convert to fusion procedures as necessary. This innovation could enhance treatment options for patients suffering from lumbar spinal degenerative diseases. The company emphasizes its focus on simplifying complex surgical solutions for improved patient outcomes.

Aurora Spine Corporation (ASAPF) announced FDA 510(k) clearance for its innovative DEXA SOLO-L spinal fusion system, a first-of-its-kind 3D printed standalone ALIF device tailored to match patients' bone density. This development enhances Aurora's DEXA Technology Platform, marking a significant advancement in spinal surgery by personalizing implants. The CEO, Trent Northcutt, emphasized the potential for increased sales and surgeon adoption. This approval follows the company's commitment to innovation and expands their product range, previously including the DEXA-C cervical implant.

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will release its financial results for Q1 2022 on May 23, 2022. This will be followed by a conference call scheduled for May 24, 2022, at 11:00 a.m. ET to discuss the results. The call can be accessed via phone at (844) 861-5497 or through a live webcast. A replay will be available until May 31, 2022. Aurora Spine specializes in designing innovative spinal implant technologies aimed at enhancing surgical outcomes.